July 24, 2014 4:48 PM ET

Pharmaceuticals

Company Overview of Sunovion Pharmaceuticals Inc.

Company Overview

Sunovion Pharmaceuticals Inc. is a research-based pharmaceutical company that is engaged in discovering, developing, and commercializing therapeutic products to help patients suffering from central nervous system (CNS) and respiratory disorders, as well as other illnesses. It focuses on treating various CNS conditions, such as anxiety, insomnia, bipolar depression, epilepsy, and schizophrenia. The company offers Latuda (lurasidone HCl) tablets for the treatment of adult patients with depressive episodes associated with bipolar I disorder, as well as with schizophrenia; Aptiom (eslicarbazepine acetate) tablets, an antiepileptic drug for use as adjunctive treatment of partial-onset seizures; a...

84 Waterford Drive

Marlborough, MA 01752

United States

Founded in 1984

2,400 Employees

Phone:

508-481-6700

Fax:

508-481-7683

Key Executives for Sunovion Pharmaceuticals Inc.

Vice Chairman
Chief Compliance & Ethics Officer and Senior Vice President
Chief General Counsel
Sunovion Vice Chair
Chief Medical Officer and Executive Vice President of Clinical Research & Medical Affairs
Compensation as of Fiscal Year 2014.

Sunovion Pharmaceuticals Inc. Key Developments

Sunovion Pharmaceuticals Inc. Presents at BIO International Convention, Jun-25-2014 10:15 AM

Sunovion Pharmaceuticals Inc. Presents at BIO International Convention, Jun-25-2014 10:15 AM. Venue: San Diego Convention Center, San Diego, California, United States.

Sunovion Pharmaceuticals Inc. Presents Data on Aptiom(R) (eslicarbazepine acetate) at American Academy of Neurology Annual Meeting

Sunovion Pharmaceuticals Inc. announced that it is presenting new findings from sub-analyses of the pooled Phase 3 studies (Studies 301, 302 and 304) evaluating the safety and efficacy of Aptiom(R) (eslicarbazepine acetate) as adjunctive treatment of partial-onset seizures. These presentations at the 66(th) American Academy of Neurology (AAN) Annual Meeting (April 26 -- May 3, Philadelphia) continue to demonstrate the importance of new treatment options for partial-onset seizures, such as APTIOM. APTIOM, a voltage-gated sodium channel blocker, is now available by prescription in pharmacies across the United States. Recognized as a new molecular entity by the U.S. Food and Drug Administration (FDA), APTIOM was approved on November 8, 2013, for use as adjunctive treatment of partial-onset seizures. Thirteen Sunovion-supported analyses will be presented at this year's AAN Annual Meeting, including eight regarding APTIOM and five presentations of new healthcare economics and outcomes research in epilepsy.

Sunovion Pharmaceuticals Inc. Announces Aptiom for the Adjunctive Treatment of Partial-Onset Seizures Now Available in U.S. Pharmacies

Sunovion Pharmaceuticals Inc. announced that Aptiom(R) (eslicarbazepine acetate), a once-daily antiepileptic drug (AED) indicated for use as adjunctive treatment of partial-onset seizures, is now available by prescription in pharmacies across the United States. APTIOM, a voltage-gated sodium channel blocker, is a new chemical entity approved by the U.S. Food and Drug Administration (FDA) on November 8, 2013, and is available in four tablet strengths (200 mg, 400 mg, 600 mg and 800 mg), which can be taken whole or crushed, with or without food. APTIOM is not classified as a controlled substance by the FDA. Sunovion Pharmaceuticals Inc. launched Aptiom (R) (eslicarbazepine acetate), a once-daily antiepileptic drug (AED) indicated for use as adjunctive treatment of partial-onset seizures.

Similar Private Companies By Industry

Company Name Region
Trana Discovery, Inc. United States
Concordia Pharmaceuticals Inc. United States
Wyeth LLC United States
Legacy Pharmaceuticals Puerto Rico, LLC United States
Global Blood Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sunovion Pharmaceuticals Inc., please visit www.sunovion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.